KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.

Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Naruto Taira, Satoshi Morita, Masakazu Toi, Shinji Ohno, Norikazu Masuda

J Clin Oncol 43(14) 1631-1637

PMID39854662
PMCIDPMC12058362
DOI10.1200/JCO-24-01673
发表日期2025-01-24
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months. Patients who have previously received pertuzumab-containing regimens as first-/second-line treatment for LA/mBC were randomly assigned 1:1 to two groups, PTC group (n = 110) and TC group (n = 109). Median OS was longer in the PTC group (median OS 36.2 v 26.5 months; hazard ratio [HR], 0.73 [one side 95% CI upper limit, 0.97]). Updated median investigator-assessed PFS (5.5 v 4.2 months; HR, 0.81 [one side 95% CI upper limit, 1.02]) were also better in the PTC group. Median PFS by independent review did not show the difference between the two groups (4.4 v 4.4 months; HR, 1.03 [one side 95% CI upper limit, 1.36]). These findings suggest that dual HER2 blockade with pertuzumab plus trastuzumab could contribute to improving OS in patients who have previously been treated with pertuzumab-containing regimens for HER2-positive LA/mBC.

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure1 个面板

FIG 2.

FIG 2. Kaplan-Meier OS curves for the intent-to-treat population. CT, computed tomography; F/U, follow-up; HR, hazard ratio; OS, overall survival; PER, pertuzumab; PTC, pertuzumab, trastuzumab and chemotherapy; TC, trastuzumab plus chemotherapy; TRA, trastuzumab.

OS_curves

Overall Survival

FIG 2. · Panel OS_curves

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel OS_curves 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
KM Figure2 个面板

FIG 4.

FIG 4. Kaplan-Meier survival curves for (A) updated investigator-assessed progression-free survival in the intent-to-treat population and (B) independent reviewer-assessed PFS in the centrally reviewed population. F/U, follow-up; HR, hazard ratio; PFS, progression-free survival; PTC, pertuzumab, trastuzumab, and chemotherapy; TC, trastuzumab plus chemotherapy

A

investigator-assessed progression-free survival

FIG 4. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
B

independent reviewer-assessed PFS

FIG 4. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. Patient disposition. IC, informed consent; ITT, intention-to-treat; PTC, pertuzumab, trastuzumab, and chemotherapy; TC, trastuzumab plus chemotherapy.
非 KM Figure
FIG 3.FIG 3. Forest plot of prespecified subgroup analysis for overall survival. a Cox proportional hazard model without adjusting for stratification factors. ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; PTC, pertuzumab, trastuzumab, and chemotherapy; TC, trastuzumab plus chemotherapy.
非 KM Figure